Panelists. Secondary Prevention of Macrovascular Events in Type 2 Diabetes: Focus on Dyslipidemia.

Slides:

Advertisements

Similar presentations

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

Advertisements

What Do We Now Know? Moderator Deepak L. Bhatt, MD, MPH Professor of Medicine, Harvard Medical School Executive Director of Interventional Cardiovascular.

Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.

By Hussam A.S. Murad and Khaled A. Mahmoud Department of Pharmacology and Therapeutics Faculty of Medicine, Ain Shams University By Hussam A.S. Murad.

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

Poor glycemic control and decreased renal function are associated with increased intrarenal RAS activity in Type 2 diabetes mellitus S. Nakatani, E.

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

From: Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver DiseaseA Systematic Review.

The Latest Lipid Guidelines:

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Diabetes and Risk of CV Outcomes

The PPAR Journey: What Can We Expect in the Future?

The PPAR Journey: What Can We Expect in the Future?

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.

An Endocrinology Clinic in Dyslipidemia

Omega-3 Prescriptions vs Supplements in Practice

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

New Insights on PPAR Agonists For Cardiovascular Disease

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Updates on CVOT Data and Clinical Comparisons That Matter

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

Select Topics in Cardiovascular Medicine

Updates on Outcomes for Novel T2D Therapies

Obesity and Dyslipidemia: How Would You Treat?

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Examining CV Effects of Basal Insulin Therapy

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Statin Class in Session

Diabetes Increases Risk of CVD

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

What's New in Dyslipidemia?

Statins and Glucose Metabolism: Are All Agents Alike?

Statin Class in Session

Section VII: Summary New focus on treating hypertension beyond the numbers Content Points: In view of current clinical understanding of the link between.

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

A Journal Club on Lipid Management:

UKPDS 35: Impact of Increasing A1c on Cardiovascular Disease in T2DM

Cardiometabolic Risk: What Can the PPAR-Alpha Agonists Teach Us?

Statins and HIV:.

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Diabetes and Cardiovascular Disease Risk: The Hard Truth

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Learning Objectives Metabolic Abnormalities Associated With T2D.

Lipid Clinic Challenge

Antihyperglycemic Therapy

Diabetes and Cardiovascular Disease Risk: The Hard Truth

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Advances in Hypertriglyceridemia Treatment

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Pharmacotherapy for Diabetic Coronary Disease:

Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis Xiaole Su, MD, Lu Zhang, MD, Jicheng Lv, MD, PhD, Jinwei Wang, PhD,

Glucose Management and Statin Therapy

Goals. The Truth About Statins: High vs Moderate Dose for Secondary Prevention of CAD.

Elevated Admission Plasma Glucose Following ACS

New Lipid-Lowering Guidelines

Lipid Updates From Spring 2019

Glucose Management and Statin Therapy

Updates on Dyslipidemia

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

Lipids, the Heart, and the Kidney

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Secondary Prevention of Macrovascular Events in Type 2 Diabetes: Focus on Dyslipidemia

Panelists

PPAR-alpha and PPAR-gamma Agonists: Target Systems

PPAR-alpha Agonists

PPAR-gamma Agonists

Genes Regulated by Glitazones

Effect of Fibrates on CV Outcomes: A Systematic Review and Meta-Analysis

PPAR-gamma Agonists: Effect on Lipids

PPAR-gamma Agonists: CV Events

Dual PPAR-alpha/gamma Agonists: Expected Targets

GALLANT 8: Effect of Tesaglitazar on HbA1c

GLAD: Effect of Tesaglitazar on Lipid Measures

Tesaglitazar: Effect on Serum Creatinine and Glomerular Filtration

Tesaglitazar: Clinical Development Summary

Muraglitazar: Effect on HbA1c and Lipid Levels

Muraglitazar: Effect on All-Cause Mortality and MACE in Patients With T2D

Muraglitazar: Clinical Development Summary

PROactive: Heart Failure

SYNCHRONY: Effect of Aleglitazar on LDL-C and HDL-C

AleNephro: Effect of Aleglitazar on Lipid Levels

SYNCHRONY: Effect of Aleglitazar on HbA1c and FPG

SYNCHRONY: Effect of Aleglitazar on Markers of Renal Function

AleNephro: Objective and Study Design

AleNephro: Effect of Aleglitazar on eGFR and SCr in Patients With Renal Impairment

AleCardio: Aleglitazar in Patients With T2D and ACS

AlePrevent: Aleglitazar in Patients With Stable CVD and Glucose Abnormalities

Moderator Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)